P Holch1,2, L Warrington2, L C A Bamforth2,3, A Keding4, L E Ziegler5, K Absolom2, C Hector1, C Harley6, O Johnson7,8, G Hall3, C Morris9, G Velikova2. 1. Psychology Group, School of Social Sciences, Faculty of Health and Social Sciences, City Campus, Leeds Beckett University, Leeds. 2. Patient Reported Outcomes Group: Leeds Institute of Cancer Studies and Pathology, Bexley Wing, St James's Hospital, University of Leeds, Leeds. 3. Leeds Teaching Hospitals NHS Trust, St James's Institute of Oncology, Bexley Wing, St James's Hospital, Leeds. 4. Department of Health Sciences, Heslington, University of York, York. 5. Institute of Health Sciences. 6. School of Healthcare: Baines Wing. 7. School of Computing, University of Leeds, Leeds. 8. X-Lab Limited, Hanover Walk, Leeds. 9. eRAPID Project Management Group, Leeds, UK.
Abstract
BACKGROUND: Significant adverse events (AE) during cancer therapy disrupt treatment and escalate to emergency admissions. Approaches to improve the timeliness and accuracy of AE reporting may improve safety and reduce health service costs. Reporting AE via patient reported outcomes (PROs), can improve clinician-patient communication and making data available to clinicians in 'real-time' using electronic PROs (ePROs) could potentially transform clinical practice by providing easily accessible records to guide treatment decisions. This manuscript describes the development of eRAPID (electronic patient self-Reporting of Adverse-events: Patient Information and aDvice) is a National Institute for Health Research-funded programme, a system for patients to self-report and manage AE online during and after cancer treatment. MATERIALS AND METHODS: A multidisciplinary team of IT experts, staff and patients developed using agile principles a secure web application interface (QStore) between an existing online questionnaire builder (QTool) displaying real-time ePRO data to clinicians in the electronic patient record at Leeds Teaching Hospitals NHS Trust. Hierarchical algorithms were developed corresponding to Common Terminology Criteria for Adverse Events grading using the QTool question dependency function. Patient advocates (N = 9), patients (N = 13), and staff (N = 19) usability tested the system reporting combinations of AE. RESULTS: The eRAPID system allows patients to report AE from home on PC, tablet or any web enabled device securely during treatment. The system generates immediate self-management advice for low or moderate AE and for severe AE advice to contact the hospital immediately. Clinicians can view patient AE data in the electronic patient record and receive email notifications when patients report severe AE. CONCLUSIONS: Evaluation of the system in a randomised controlled trial in breast, gynaecological and colorectal cancer patients undergoing systemic therapy is currently underway. To adapt eRAPID for different treatment groups, pilot studies are being undertaken with patients receiving pelvic radiotherapy and upper gastrointestinal surgery. ISRCTN88520246.
BACKGROUND: Significant adverse events (AE) during cancer therapy disrupt treatment and escalate to emergency admissions. Approaches to improve the timeliness and accuracy of AE reporting may improve safety and reduce health service costs. Reporting AE via patient reported outcomes (PROs), can improve clinician-patient communication and making data available to clinicians in 'real-time' using electronic PROs (ePROs) could potentially transform clinical practice by providing easily accessible records to guide treatment decisions. This manuscript describes the development of eRAPID (electronic patient self-Reporting of Adverse-events: Patient Information and aDvice) is a National Institute for Health Research-funded programme, a system for patients to self-report and manage AE online during and after cancer treatment. MATERIALS AND METHODS: A multidisciplinary team of IT experts, staff and patients developed using agile principles a secure web application interface (QStore) between an existing online questionnaire builder (QTool) displaying real-time ePRO data to clinicians in the electronic patient record at Leeds Teaching Hospitals NHS Trust. Hierarchical algorithms were developed corresponding to Common Terminology Criteria for Adverse Events grading using the QTool question dependency function. Patient advocates (N = 9), patients (N = 13), and staff (N = 19) usability tested the system reporting combinations of AE. RESULTS: The eRAPID system allows patients to report AE from home on PC, tablet or any web enabled device securely during treatment. The system generates immediate self-management advice for low or moderate AE and for severe AE advice to contact the hospital immediately. Clinicians can view patient AE data in the electronic patient record and receive email notifications when patients report severe AE. CONCLUSIONS: Evaluation of the system in a randomised controlled trial in breast, gynaecological and colorectal cancer patients undergoing systemic therapy is currently underway. To adapt eRAPID for different treatment groups, pilot studies are being undertaken with patients receiving pelvic radiotherapy and upper gastrointestinal surgery. ISRCTN88520246.
Authors: Alexander C Newsham; Colin Johnston; Geoff Hall; Michael G Leahy; Adam B Smith; Aditya Vikram; Aine M Donnelly; Galina Velikova; Peter J Selby; Sheila E Fisher Journal: Comput Biol Med Date: 2011-06-23 Impact factor: 4.589
Authors: Galina Velikova; Laura Booth; Adam B Smith; Paul M Brown; Pamela Lynch; Julia M Brown; Peter J Selby Journal: J Clin Oncol Date: 2004-02-15 Impact factor: 44.544
Authors: Bernhard Holzner; Johannes M Giesinger; Jakob Pinggera; Stefan Zugal; Felix Schöpf; Anne S Oberguggenberger; Eva M Gamper; August Zabernigg; Barbara Weber; Gerhard Rumpold Journal: BMC Med Inform Decis Mak Date: 2012-11-09 Impact factor: 2.796
Authors: Monika Alise Johansen; Eva Henriksen; Alexander Horsch; Tibor Schuster; Gro K Rosvold Berntsen Journal: J Med Internet Res Date: 2012-10-03 Impact factor: 5.428
Authors: Frank J Penedo; Laura B Oswald; Joshua P Kronenfeld; Sofia F Garcia; David Cella; Betina Yanez Journal: Lancet Oncol Date: 2020-05 Impact factor: 41.316
Authors: R D Nipp; N K Horick; A M Deal; L J Rogak; C Fuh; J A Greer; A C Dueck; E Basch; J S Temel; A El-Jawahri Journal: Ann Oncol Date: 2020-01 Impact factor: 32.976
Authors: H S Richards; J M Blazeby; A Portal; R Harding; T Reed; T Lander; K A Chalmers; R Carter; R Singhal; K Absolom; G Velikova; K N L Avery Journal: BMC Cancer Date: 2020-06-10 Impact factor: 4.430
Authors: Sanna Iivanainen; Jussi Ekstrom; Henri Virtanen; Vesa V Kataja; Jussi P Koivunen Journal: BMC Med Inform Decis Mak Date: 2021-06-30 Impact factor: 2.796
Authors: Patricia Holch; Simon Pini; Ann M Henry; Susan Davidson; Jacki Routledge; Julia Brown; Kate Absolom; Alexandra Gilbert; Kevin Franks; Claire Hulme; Carolyn Morris; Galina Velikova Journal: Pilot Feasibility Stud Date: 2018-06-05